trending Market Intelligence /marketintelligence/en/news-insights/trending/N4yJhz-KLoQ1Zzr7s-a5DQ2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Cytokinetics granted FDA orphan-drug tag for ALS drug

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Cytokinetics granted FDA orphan-drug tag for ALS drug

Cytokinetics Inc.'s reldesemtiv received the U.S. Food and Drug Administration's orphan drug designation to treat patients with amyotrophic lateral sclerosis.

ALS, also known as motor neuron disease or Lou Gehrig's disease, is a progressive nervous system condition that causes the death of nerve cells that control voluntary muscles. The disease is estimated to affect about 20,000 individuals in the U.S., with about 5,000 new cases diagnosed annually, Cytokinetics said in a Dec. 18 press release. Only about 10% of patients survive for more than a decade after diagnosis, with most deaths caused by respiratory failure due to diminished strength in the skeletal muscles responsible for breathing.

The U.S. FDA's orphan-drug designation encourages companies to develop cures for rare diseases by offering tax reductions, fee exemptions and a license to be the sole sellers of approved treatments for seven years.

Previously, the U.S. regulator and the European Medicines Agency have classified reldesemtiv as an orphan medicinal product for the potential treatment of spinal muscular atrophy, which is a genetic disease characterized by progressive, debilitating muscle weakness.

Cytokinetics in May said reldesemtiv failed to improve lung function in patients with ALS during a mid-stage study.

Reldesemtiv is being developed by Cytokinetics in collaboration with Tokyo-based Astellas Pharma Inc.